131156-47-3

Basic information

• Product Name: α-L-Xylofuranose,1,2:3,5-bis-O-(1-Methylethylidene)-
• Synonyms: α-L-Xylofuranose,1,2:3,5-bis-O-(1-Methylethylidene)-;1,2:3,5-DI-O-ISOPROPYLIDENE-ALPHA-L-XYLOFURANOSE;(-)-1,2:3,5-di-O-isopropylidene-α-L-xylofuranose;(3aS,3bR,7aS,8aS)-2,2,5,5-tetramethyltetrahydro-3aH-[1,3]dioxolo[4',5':4,5]furo[3,2-d][1,3]dioxine
• CAS NO: 131156-47-3
• Molecular Formula: C₁₁H₁₈O₅
• Molecular Weight: 230.25762
• Mol File: 131156-47-3.mol
• Article Data: 24

Chemical Properties

• Melting Point: 39-40 °C
• Boiling Point: 272.2±35.0 °C(Predicted)
• Appearance: /
• Density: 1.112±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: α-L-Xylofuranose,1,2:3,5-bis-O-(1-Methylethylidene)-(CAS DataBase Reference)
• NIST Chemistry Reference: α-L-Xylofuranose,1,2:3,5-bis-O-(1-Methylethylidene)-(131156-47-3)
• EPA Substance Registry System: α-L-Xylofuranose,1,2:3,5-bis-O-(1-Methylethylidene)-(131156-47-3)

Safety Data

• Hazardous Substances Data: 131156-47-3(Hazardous Substances Data)

Upstream product

• 87-72-9 L-(-)-xylose 
• 67-64-1 acetone 
• 609-06-3 L-xylose 
• 532-20-7 D-xylofuranose 
• 58-86-6 D-xylose 
• 87-72-9 D-Xylose 
• 87-72-9 L-xylopyranose 
• 104-53-0 3-phenyl-propionaldehyde 
• 41546-31-0 L-xylose 
• 41546-30-9 β-L-arabinose 
• 18467-77-1 dikegulac 
• 63941-79-7 2,3:4,6-di-O-isopropylidene-2-keto-L-gulonyl chloride 

Downstream Products

• 6422-34-0 L-gulomethylonic acid 
• 6422-34-0 L-idomethylonic acid 
• 50600-39-0 O¹,O²-isopropylidene-5-iodo-5-deoxy-α-L-xylofuranose 
• 218621-71-7 6-hydroxy-2,2-dimethyl-5-(4-methylphenylsulfonyloxymethyl)-(3aS,5S,6R,6aS)-perhydrofuro[2,3-d][1,3]dioxole 
• 20031-21-4 1,2-O-isopropylidene-α-D-xylose 
• 1333476-27-9 C₁₉H₂₂O₈ 
• 1333476-29-1 diethyl (5S)-(3-O-benzyl-1,2-O-isopropylidene-α-L-xylofuranos-5-C-yl)phoshonate 
• 391201-57-3 [(3aS,5S,6R,6aS)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl]methanol 
• 145772-63-0 (3aS,5R,6R,6aS)-6-Benzyloxy-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxole-5-carbaldehyde 
• 6022-96-4 5-O-benzoyl-α-D-xylofuranose 
• 1103738-20-0 morpholine (3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carboxylic acid 
• 73-03-0 cordycepin 
• 862179-59-7 5'-O-(tert-butyldiphenylsilyl)-3'-deoxy-adenosine 
• 865853-43-6 (3R,5S)-5-(methylacetoxytetrahydrofuran)-2,3-diyl diacetate 

Relevant articles and documents

Process development of sotagliflozin, a dual inhibitor of sodium- Glucose cotransporter-1/2 for the treatment of diabetes

The development of an efficient manufacturing process for sotagliflozin (LX4211), a dual inhibitor of sodium- glucose cotransporter-1/2 (SGLT-1/2) for the treatment of diabetes, is described. Sotagliflozin features five contiguous chiral centers on the carbohydrate core flanked by a thioether group and a biaryl moiety. Three chiral centers are obtained from the starting material L-xylose, while the other two were established (or modified) via three highly stereoselective transformations: Luche reduction (dr: 97/3), dynamic kinetic resolution of anomeric hemiacetal (dr: 95/5), and Lewis acid-promoted thiolation (dr: 1000/ 1). Global deprotection of the resulting penultimate intermediate with catalytic sodium methoxide followed by recrystallization furnishes sotagliflozin. The longest linear sequence consists of 10 steps from L-xylose with an overall yield of 40%. This process has been performed on multi-hundred kilogram batches to satisfy the drug substance development demands.

Novel synthesis method of furan xylose derivatives

The invention discloses a novel synthesis method of furan xylose derivatives, which comprises the following steps: L-(-) xylose and acetone are used as starting materials, and only 2-5 equivalents ofacetone are needed under the catalysis of acholine chlor

CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS

The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.